{"PubmedBookArticle": [], "PubmedArticle": [{"MedlineCitation": {"KeywordList": [["Antiviral", "COVID-19", "Immunomodulation", "Inflammation", "M(pro)", "Pneumonia", "SARS-CoV-2", "Shufeng Jiedu"]], "SpaceFlightMission": [], "InvestigatorList": [], "OtherAbstract": [], "OtherID": [], "CitationSubset": ["IM"], "GeneralNote": [], "PMID": "33158717", "DateCompleted": {"Year": "2021", "Month": "04", "Day": "28"}, "DateRevised": {"Year": "2022", "Month": "12", "Day": "21"}, "Article": {"ArticleDate": [{"Year": "2020", "Month": "10", "Day": "22"}], "Language": ["eng"], "ELocationID": ["10.1016/j.phymed.2020.153390", "S0944-7113(20)30221-X"], "Journal": {"ISSN": "1618-095X", "JournalIssue": {"Volume": "85", "PubDate": {"Year": "2021", "Month": "May"}}, "Title": "Phytomedicine : international journal of phytotherapy and phytopharmacology", "ISOAbbreviation": "Phytomedicine"}, "ArticleTitle": "Shufeng Jiedu, a promising herbal therapy for moderate COVID-19:Antiviral and anti-inflammatory properties, pathways of bioactive compounds, and a clinical real-world pragmatic study.", "Pagination": {"StartPage": "153390", "MedlinePgn": "153390"}, "Abstract": {"AbstractText": ["Shufeng Jiedu capsules (SFJDC), a patented herbal drug composed of eight medicinal plants, is used for the treatment of different viral respiratory tract infectious diseases. Based on its antiviral, anti-inflammatory and immunoregulatory activity in acute lung injury, SFJDC might be a promising candidate for the treatment of COVID-19.", "To evaluate the antiviral and anti-inflammatory properties and to discover the mechanism of action of SFJDC as a potential drug for the treatment of COVID-19. Furthermore, the study should determine the clinical effectiveness of SFJDC for the treatment of COVID-19.", "We analyzed the antiviral and anti-inflammatory effects of SFJDC in a HCoV-229E mouse model on lung index, virus load in the lung, the release of cytokines, and on T- and B-lymphocytes. The mechanism of action was further investigated by network analysis. Additionally, we investigated data from a clinical pragmatic real-world study for patients with confirmed COVID-19, to evaluate the clinical effect of SFJDC and to determine the best time to start the treatment.", "SFJDC significantly reduced the virus load in the lung of HCoV-229E mice (from 1109.29 \u00b1 696.75 to 0 \u00b1 0 copies/ml), decreased inflammatory factors IL-6, IL-10, TNF-\u03b1, and IFN-\u03b3 in the lung, and increased the amount of CD4<sup>+</sup> and CD8<sup>+</sup> cells in the blood compared to the model group. Network analysis revealed that SFJDC reduces the activity of NF\u03baB via several signaling pathways. Quercetin, wogonin, and polydatin bind directly to the main protease (M<sup>pro</sup>) of SARS-CoV-2. Clinical data showed that SFJDC, added to standard antiviral therapy (AVD), significantly reduced the clinical recovery time of COVID-19 and fatigue (from 3.55 \u00b1 4.09 to 1.19 \u00b1 2.28 days) as well as cough (from 5.67 \u00b1 5.64 to 3.47 \u00b1 3.75) days compared to AVD alone. SFJDC therapy was significantly more effective when used within the first 8 days after the onset of symptoms.", "SFJDC might be a promising drug for the treatment of COVID-19, but large-scale randomized, double-blinded, placebo-controlled clinical trials are needed to complement the real-world evidence. It might be beneficial to start SFJDC treatment as early as possible in suspected cases of COVID-19."], "CopyrightInformation": "Copyright \u00a9 2020 The Author(s). Published by Elsevier GmbH.. All rights reserved."}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Shanghai Public Health Clinical Center, Fudan University, Shanghai, 201508, P.R. China. Electronic address: hello0410@126.com."}], "LastName": "Xia", "ForeName": "Lu", "Initials": "L"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing, 100025, P.R. China. Electronic address: yjshi@icmm.ac.cn."}], "LastName": "Shi", "ForeName": "Yujing", "Initials": "Y"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Shanghai Institute for Advanced Immunochemical Studies, Shanghai Tech University, Shanghai, 201210, P.R. China. Electronic address: Sujie@shanghaitech.edu.cn."}], "LastName": "Su", "ForeName": "Jie", "Initials": "J"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "HanseMerkur Center for Traditional Chinese Medicine at the University Medical Center, Hamburg-Eppendorf, Hamburg, 20251, Germany. Electronic address: Friedemann@tcm-am-uke.de."}], "LastName": "Friedemann", "ForeName": "Thomas", "Initials": "T"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Emergency Department, Zhongshan Hospital, Fudan University, Shanghai 200032, P.R. China."}], "LastName": "Tao", "ForeName": "Zhenggang", "Initials": "Z"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Shanghai Public Health Clinical Center, Fudan University, Shanghai, 201508, P.R. China."}], "LastName": "Lu", "ForeName": "Yunfei", "Initials": "Y"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Shanghai Public Health Clinical Center, Fudan University, Shanghai, 201508, P.R. China."}], "LastName": "Ling", "ForeName": "Yun", "Initials": "Y"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Shanghai Public Health Clinical Center, Fudan University, Shanghai, 201508, P.R. China."}], "LastName": "Lv", "ForeName": "Ying", "Initials": "Y"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing, 100025, P.R. China."}], "LastName": "Zhao", "ForeName": "Ronghua", "Initials": "R"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing, 100025, P.R. China."}], "LastName": "Geng", "ForeName": "Zihan", "Initials": "Z"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing, 100025, P.R. China. Electronic address: xlcui@icmm.ac.cn."}], "LastName": "Cui", "ForeName": "Xiaolan", "Initials": "X"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Shanghai Public Health Clinical Center, Fudan University, Shanghai, 201508, P.R. China."}], "LastName": "Lu", "ForeName": "Hongzhou", "Initials": "H"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "HanseMerkur Center for Traditional Chinese Medicine at the University Medical Center, Hamburg-Eppendorf, Hamburg, 20251, Germany. Electronic address: Schroeder@tcm-am-uke.de."}], "LastName": "Schr\u00f6der", "ForeName": "Sven", "Initials": "S"}], "PublicationTypeList": ["Journal Article", "Pragmatic Clinical Trial"]}, "MedlineJournalInfo": {"Country": "Germany", "MedlineTA": "Phytomedicine", "NlmUniqueID": "9438794", "ISSNLinking": "0944-7113"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Anti-Inflammatory Agents"}, {"RegistryNumber": "0", "NameOfSubstance": "Antiviral Agents"}, {"RegistryNumber": "0", "NameOfSubstance": "Drug Combinations"}, {"RegistryNumber": "0", "NameOfSubstance": "Drugs, Chinese Herbal"}, {"RegistryNumber": "0", "NameOfSubstance": "Indoles"}, {"RegistryNumber": "0", "NameOfSubstance": "NF-kappa B"}, {"RegistryNumber": "0", "NameOfSubstance": "lopinavir-ritonavir drug combination"}, {"RegistryNumber": "0", "NameOfSubstance": "shufeng jiedu"}, {"RegistryNumber": "2494G1JF75", "NameOfSubstance": "Lopinavir"}, {"RegistryNumber": "93M09WW4RU", "NameOfSubstance": "umifenovir"}, {"RegistryNumber": "EC 3.4.22.-", "NameOfSubstance": "3C-like protease, SARS coronavirus"}, {"RegistryNumber": "EC 3.4.22.28", "NameOfSubstance": "Coronavirus 3C Proteases"}, {"RegistryNumber": "O3J8G9O825", "NameOfSubstance": "Ritonavir"}], "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "Adult"}, {"QualifierName": [], "DescriptorName": "Animals"}, {"QualifierName": [], "DescriptorName": "Anti-Inflammatory Agents"}, {"QualifierName": ["therapeutic use"], "DescriptorName": "Antiviral Agents"}, {"QualifierName": ["drug effects"], "DescriptorName": "Coronavirus 229E, Human"}, {"QualifierName": ["antagonists & inhibitors"], "DescriptorName": "Coronavirus 3C Proteases"}, {"QualifierName": [], "DescriptorName": "Drug Combinations"}, {"QualifierName": ["therapeutic use"], "DescriptorName": "Drugs, Chinese Herbal"}, {"QualifierName": [], "DescriptorName": "Female"}, {"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": ["therapeutic use"], "DescriptorName": "Indoles"}, {"QualifierName": ["therapeutic use"], "DescriptorName": "Lopinavir"}, {"QualifierName": ["virology"], "DescriptorName": "Lung"}, {"QualifierName": [], "DescriptorName": "Male"}, {"QualifierName": [], "DescriptorName": "Mice"}, {"QualifierName": [], "DescriptorName": "Mice, Inbred BALB C"}, {"QualifierName": [], "DescriptorName": "Middle Aged"}, {"QualifierName": [], "DescriptorName": "Molecular Docking Simulation"}, {"QualifierName": [], "DescriptorName": "NF-kappa B"}, {"QualifierName": ["therapeutic use"], "DescriptorName": "Ritonavir"}, {"QualifierName": ["drug effects"], "DescriptorName": "SARS-CoV-2"}, {"QualifierName": [], "DescriptorName": "Signal Transduction"}, {"QualifierName": [], "DescriptorName": "Viral Load"}, {"QualifierName": [], "DescriptorName": "COVID-19 Drug Treatment"}], "CoiStatement": "None."}, "PubmedData": {"ReferenceList": [{"ReferenceList": [], "Reference": [{"Citation": "Anglemyer A., Horvath H.T., Bero L. Healthcare outcomes assessed with observational study designs compared with those assessed in randomized trials. Cochrane Database Syst. Rev. 2014 doi: 10.1002/14651858.MR000034.pub2.", "ArticleIdList": ["10.1002/14651858.MR000034.pub2", "PMC8191367", "24782322"]}, {"Citation": "Cao B., et al. A Trial of Lopinavir\u2013Ritonavir in Adults Hospitalized with Severe Covid-19. N. Engl. J. Med. 2020;382:1787\u20131799.", "ArticleIdList": ["PMC7121492", "32187464"]}, {"Citation": "Chen J., Lin S., Niu C., Xiao Q. Clinical evaluation of Shufeng Jiedu Capsules combined with umifenovir (Arbidol) in the treatment of common-type COVID-19: a retrospective study. Expert Rev. Respir. Med. 2020:1\u20139. doi: 10.1080/17476348.2020.1822741.", "ArticleIdList": ["10.1080/17476348.2020.1822741", "PMC7544967", "32941741"]}, {"Citation": "Chen J., et al. Efficacies of lopinavir/ritonavir and abidol in the treatment of novel coronavirus pneumonia. Chinese J. Infect. Dis. 2020;38 E008\u2013E008."}, {"Citation": "Guimar\u00e3es C.R.W., Cardozo M. MM-GB/SA rescoring of docking poses in structure-based lead optimization. J. Chem. Inf. Model. 2008;48:958\u2013970.", "ArticleIdList": ["18422307"]}, {"Citation": "Jean S.S., Lee P.I., Hsueh P.R. Treatment options for COVID-19: The reality and challenges. Journal of Microbiology, Immunology and Infection. 2020;53", "ArticleIdList": ["PMC7129535", "32307245"]}, {"Citation": "Ji S., et al. Unique synergistic antiviral effects of Shufeng Jiedu Capsule and oseltamivir in influenza A viral-induced acute exacerbation of chronic obstructive pulmonary disease. Biomed. Pharmacother. 2020;121", "ArticleIdList": ["31734578"]}, {"Citation": "Kai-Wang To K., et al. Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study. Lancet Infect. Dis. 2020;20:565\u2013574.", "ArticleIdList": ["PMC7158907", "32213337"]}, {"Citation": "Kumar A., Dhawair S., Aggarwal B.B. Emodin (3-methyl-1,6,8-trihydroxyanthraquinone) inhibits TNF-induced NF-\u03baB activation, I\u03baB degradation, and expression of cell surface adhesion proteins in human vascular endothelial cells. Oncogene. 1998;17:913\u2013918.", "ArticleIdList": ["9780008"]}, {"Citation": "Leung P.C. The efficacy of Chinese medicine for SARS: A review of Chinese publications after the crisis. American Journal of Chinese Medicine. 2007;35:575\u2013581.", "ArticleIdList": ["17708624"]}, {"Citation": "Li J.H., Wang R.Q., Guo W.J., Li J.S. Efficacy and safety of traditional Chinese medicine for the treatment of influenza A (H1N1): A meta-analysis. J. Chinese Med. Assoc. 2016;79:281\u2013291.", "ArticleIdList": ["26935853"]}, {"Citation": "Li Y., et al. Anti-inflammatory effects of Shufengjiedu capsule for upper respiratory infection via the ERK pathway. Biomed. Pharmacother. 2017;94:758\u2013766.", "ArticleIdList": ["28802227"]}, {"Citation": "Li H., et al. Updated approaches against SARS-CoV-2. Antimicrobial Agents and Chemotherapy. 2020;64:1\u20137.", "ArticleIdList": ["PMC7269512", "32205349"]}, {"Citation": "Li H., et al. SARS-CoV-2 and viral sepsis: observations and hypotheses. The Lancet. 2020;395:1517\u20131520.", "ArticleIdList": ["PMC7164875", "32311318"]}, {"Citation": "National Health Commission & State Administration of Traditional Chinese Medicine Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia. Trial Vers. 2020"}, {"Citation": "NHC . H1N1 influenza diagnosis and treatment plan; 2010. National Health Commission of the People\u2019s Republic of China."}, {"Citation": "Qu X., et al. Observation on the clinical effect of Shufeng Jiedu Capsule combined with Arbidol Hydrochloride Capsules in the treatment of COVID-19.pdf. Chinese Tradit. Herb. Drugs CN. 2020:12\u20131108."}, {"Citation": "Sahpaz S., Garbacki N., Tits M., Bailleul F. Isolation and pharmacological activity of phenylpropanoid esters from Marrubium vulgare. J. Ethnopharmacol. 2002;79:389\u2013392.", "ArticleIdList": ["11849848"]}, {"Citation": "Tao Z., et al. Shufeng Jiedu Capsule protect against acute lung injury by suppressing the MAPK/NF-\u03baB pathway. BioScience Trends. 2014;8:45\u201351.", "ArticleIdList": ["24647112"]}, {"Citation": "Tao Z., et al. Therapeutic Mechanistic Studies of ShuFengJieDu Capsule in an Acute Lung Injury Animal Model Using Quantitative Proteomics Technology. J. Proteome Res. 2017;16:4009\u20134019.", "ArticleIdList": ["28880561"]}, {"Citation": "Tao, Z. et\u00a0al. Quantitative Proteomics Analysis of Systemic Responses and Biological Mechanisms of ShuFengJieDu Capsule Using H1N1-Infected RAW264.7 Cells. (2020). doi:10.1021/acsomega.0c01545.", "ArticleIdList": ["PMC7331074", "32637816"]}, {"Citation": "Wang X., et al. PharmMapper 2017 update: a web server for potential drug target identification with a comprehensive target pharmacophore database. Nucleic Acids Res. 2017;45", "ArticleIdList": ["PMC5793840", "28472422"]}, {"Citation": "Wang Z., et al. Phytochemistry, pharmacology, quality control and future research of Forsythia suspensa (Thunb.) Vahl: A review. Journal of Ethnopharmacology. 2018;210:318\u2013339.", "ArticleIdList": ["28887216"]}, {"Citation": "Wang, F. et\u00a0al. 2020 Characteristics of Peripheral Lymphocyte Subset Alteration in COVID-19 Pneumonia. doi:10.1093/infdis/jiaa150.", "ArticleIdList": ["PMC7184346", "32227123"]}, {"Citation": "Xi Z., et al. Effect of Shufengjiedu capsule on the fever caused by viral upper respiratory tract infection: A report of 130 cases. J Tradit Chin Med. 2010;51:426\u2013427."}, {"Citation": "Yuan Y., et al. Shufeng Jiedu Capsules Alleviate Lipopolysaccharide-Induced Acute Lung Inflammatory Injury via Activation of GPR18 by Verbenalin. Cell. Physiol. Biochem. 2018;50:552\u2013568.", "ArticleIdList": ["30308517"]}, {"Citation": "Yum H.-K., et al. Involvement of Phosphoinositide 3-Kinases in Neutrophil Activation and the Development of Acute Lung Injury. J. Immunol. 2001;167:6601\u20136608.", "ArticleIdList": ["11714830"]}, {"Citation": "Zheng, X.-Y. et\u00a0al. Emodin-induced autophagy against cell apoptosis through the PI3K/AKT/mTOR pathway in human hepatocytes. (2019). doi:10.2147/DDDT.S204958.", "ArticleIdList": ["PMC6734549", "31564833"]}, {"Citation": "Zhong W.T., et al. Phillyrin attenuates LPS-induced pulmonary inflammation via suppression of MAPK and NF-\u03baB activation in acute lung injury mice. Fitoterapia. 2013;90:132\u2013139.", "ArticleIdList": ["23751215"]}, {"Citation": "Zuidgeest M.G.P., et al. Series: Pragmatic trials and real world evidence: Paper 1. Introduction. J. Clin. Epidemiol. 2017;88:7\u201313.", "ArticleIdList": ["28549929"]}]}], "History": [{"Year": "2020", "Month": "7", "Day": "13"}, {"Year": "2020", "Month": "9", "Day": "28"}, {"Year": "2020", "Month": "10", "Day": "15"}, {"Year": "2020", "Month": "11", "Day": "8", "Hour": "6", "Minute": "0"}, {"Year": "2021", "Month": "4", "Day": "29", "Hour": "6", "Minute": "0"}, {"Year": "2020", "Month": "11", "Day": "7", "Hour": "5", "Minute": "27"}, {"Year": "2020", "Month": "10", "Day": "22"}], "PublicationStatus": "ppublish", "ArticleIdList": ["33158717", "PMC7581328", "10.1016/j.phymed.2020.153390", "S0944-7113(20)30221-X"]}}]}